Jéssica L. Antunes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jéssica L. Antunes has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Ana Cláudia Paiva-Santos
Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Coimbra, Portugal
2 shared publications - Francisco Veiga
Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Coimbra, Portugal
2 shared publications - Patrícia C. Pires
Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Azinhaga de Santa Comba, Coimbra, Portugal
2 shared publications - Joana Amado
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal
1 shared publication
Latest Publications
- Open Access
- 20 March 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (3) , 998
Nanosystems, Drug Molecule Functionalization and Intranasal Delivery: An Update on the Most Promising Strategies for Increasing the Therapeutic Efficacy of Antidepressant and Anxiolytic Drugs
Depression and anxiety are high incidence and debilitating psychiatric disorders, usually treated by antidepressant or anxiolytic drug administration, respectively. Nevertheless, treatment is usually given through the oral route, but the low permeability of the blood–brain barrier reduces the amount of drug that will be able to reach it, thus consequently reducing the therapeutic efficacy. Which is why it is imperative to find new solutions to make these treatments more effective, safer, and faster. To overcome this obstacle, three main strategies have been used to improve brain drug targeting: the intranasal route of administration, which allows the drug to be directly transported to the brain by neuronal pathways, bypassing the blood–brain barrier and avoiding the hepatic and gastrointestinal metabolism; the use of nanosystems for drug encapsulation, including polymeric and lipidic nanoparticles, nanometric emulsions, and nanogels; and drug molecule functionalization by ligand attachment, such as peptides and polymers. Pharmacokinetic and pharmacodynamic in vivo studies’ results have shown that intranasal administration can be more efficient in brain targeting than other administration routes, and that the use of nanoformulations and drug functionalization can be quite advantageous in increasing brain–drug bioavailability. These strategies could be the key to future improved therapies for depressive and anxiety disorders.
- 20 March 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (3) , 998
Open AccessNanosystems, Drug Molecule Functionalization and Intranasal Delivery: An Update on the Most Promising Strategies for Increasing the Therapeutic Efficacy of Antidepressant and Anxiolytic Drugs
Depression and anxiety are high incidence and debilitating psychiatric disorders, usually treated by antidepressant or anxiolytic drug administration, respectively. Nevertheless, treatment is usually given through the oral route, but the low permeability of the blood–brain barrier reduces the amount of drug that will be able to reach it, thus consequently reducing the therapeutic efficacy. Which is why it is imperative to find new solutions to make these treatments more effective, safer, and faster. To overcome this obstacle, three main strategies have been used to improve brain drug targeting: the intranasal route of administration, which allows the drug to be directly transported to the brain by neuronal pathways, bypassing the blood–brain barrier and avoiding the hepatic and gastrointestinal metabolism; the use of nanosystems for drug encapsulation, including polymeric and lipidic nanoparticles, nanometric emulsions, and nanogels; and drug molecule functionalization by ligand attachment, such as peptides and polymers. Pharmacokinetic and pharmacodynamic in vivo studies’ results have shown that intranasal administration can be more efficient in brain targeting than other administration routes, and that the use of nanoformulations and drug functionalization can be quite advantageous in increasing brain–drug bioavailability. These strategies could be the key to future improved therapies for depressive and anxiety disorders.
- Open Access
- 1 December 2022
- Published by MDPI AG in Engineering Proceedings
- Vol. 31 (1) , 50
Brain Targeting of Antidepressant and Anxiolytic Drugs
Depression and anxiety are high incidence and debilitating psychiatric disorders, usually treated by antidepressant or anxiolytic drug administration, respectively. Nevertheless, this treatment is usually administered orally, but the low permeability of the blood–brain barrier, which serves many functions such as being a barrier to prevent the entry of external substances into the brain, reduces the amount of drugs that will be able to reach the brain, also reducing, consequently, therapeutic efficacy. This is why new solutions have been tried, i.e., to make these treatments more effective, safer, and faster. To overcome this obstacle, in the articles analyzed in this work, three main strategies were used to improve brain drug targeting: the intranasal route of administration, which allows the drug to be directly transported to the brain by neuronal pathways (olfactory and trigeminal nerves), bypassing the blood–brain barrier and avoiding hepatic and gastrointestinal metabolism; the use of nanosystems for drug encapsulation, including polymeric and lipidic nanoparticles, nanometric emulsions and nanogels; and drug molecule functionalization, by the attachment of ligands such as peptides and polymers. Pharmacokinetic and pharmacodynamic results showed that intranasal administration can be more efficient in brain targeting than other routes (such as intravenous or oral administration), as well as the use of nanoformulations and drug functionalization, which are also quite beneficial in increasing brain drug bioavailability.
- 1 December 2022
- Published by MDPI AG in Engineering Proceedings
- Vol. 31 (1) , 50
Open AccessBrain Targeting of Antidepressant and Anxiolytic Drugs
Depression and anxiety are high incidence and debilitating psychiatric disorders, usually treated by antidepressant or anxiolytic drug administration, respectively. Nevertheless, this treatment is usually administered orally, but the low permeability of the blood–brain barrier, which serves many functions such as being a barrier to prevent the entry of external substances into the brain, reduces the amount of drugs that will be able to reach the brain, also reducing, consequently, therapeutic efficacy. This is why new solutions have been tried, i.e., to make these treatments more effective, safer, and faster. To overcome this obstacle, in the articles analyzed in this work, three main strategies were used to improve brain drug targeting: the intranasal route of administration, which allows the drug to be directly transported to the brain by neuronal pathways (olfactory and trigeminal nerves), bypassing the blood–brain barrier and avoiding hepatic and gastrointestinal metabolism; the use of nanosystems for drug encapsulation, including polymeric and lipidic nanoparticles, nanometric emulsions and nanogels; and drug molecule functionalization, by the attachment of ligands such as peptides and polymers. Pharmacokinetic and pharmacodynamic results showed that intranasal administration can be more efficient in brain targeting than other routes (such as intravenous or oral administration), as well as the use of nanoformulations and drug functionalization, which are also quite beneficial in increasing brain drug bioavailability.